Biological activities of guanidine compounds, 2008-2012 update

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 8, 2013, Pages 965-995

  Saczewski, Franciszek ^a   Balewski, Łukasz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Biological activities; Guanidines; Structure; Therapeutic applications

Indexed keywords

ALEXIDINE; ALTEPLASE; AUROVERTIN; BUFORMIN; CAPTOPRIL; CARIPORIDE; CLONIDINE; ENIPORIDE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; GUANFACINE; GUANIDINE DERIVATIVE; LOSARTAN; METFORMIN; OLIGOMYCIN; PHENFORMIN; SEMAPIMOD; SUBIPORIDE; UNCLASSIFIED DRUG; ZONIPORIDE;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTICOAGULANT THERAPY; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ATTENTION DEFICIT DISORDER; BIOLOGICAL ACTIVITY; CARDIOVASCULAR FUNCTION; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; FUNGICIDAL ACTIVITY; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION PREVENTION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATENT; REVIEW;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; GUANIDINES; HUMANS; PATENTS AS TOPIC; PEPTIDES; PEPTIDOMIMETICS;

EID: 84880678749     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.788645     Document Type: Review

References (212)

1. Saczewski F, Balewski ? Biological activities of guanidine compounds Expert Opin Ther Patents 2009;19:1417-48
2. Berlinck RGS, Burtoloso ACB, Kossuga MH The chemistry and biology of organic guanidine derivatives Nat Prod Rep 2008;25:919-54
3. Berlinck RGS, Burtoloso ACB, Trindade-Silva AE, et al The chemistry and biology of organic guanidine derivatives Nat Prod Rep 2010;27:1871-907
4. Castagnolo D, Schenone S, Botta M Guanylated diamines, triamines, and polyamines: chemistry and biological properties Chem Rev 2011;111:5247-300
5. Rauws TRM, Maes BUW Transition metal-catalyzed N-arylations of amidines and guanidines Chem Soc Rev 2012;41:2463-97
6. Coles MP Bicyclic-guanidines,-guanidates and-guanidinium salts ide ranging applications from a simple family of molecules Chem Commun 2009;3659-76
7. Taylor JE, Bull SD, Williams MJ Amidines, isothioureas, and guanidines as nucleophilic catalysts Chem Soc Rev 2012;41:2109-21
8. Shao J, Chen W, Giulianotti MA, et al Palladium-catalyzed C-H functionalization using guanidine as a directing group: ortho arylation and olefination of arylguanidines Org Lett 2012;14:5452-5
9. Xing H, Zhang Y, Lai Y, et al Synthesis of symmetrical and unsymmetrical N, N'-diaryl guanidines via copper/Nmethylglycine-catalyzed arylation of guanidine nitrate J Org Chem 2012;77:5449-53
10. Santana AG, Francisco CG, Suarez E, et al Synthesis of guanidines from azides: a general and straightforward methodology in carbohydrate chemistry J Org Chem 2010;75:5371-4
11. Sun J, Miller JM, Beig A, et al Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidine functionality Expert Opin Drug Metab Toxicol 2011;7:313-23
12. Cooley CB, Trantow BM, Nederberg F, et al Oligocarbonate molecular transporters: oligomerization-based syntheses and cell-penetrating studies J Am Chem Soc 2009;131:16401-3
13. Hamilton SK, Harth E Molecular dendritic transporter nanoparticle vectors provide efficient intracellular delivery of properties ACS Nano 2009;3:402-10
14. Bagnacani V, Franceschi V, Fantuzzi L, et al Lower rim guanidinocalix[4]arenes: macrocyclic nonviral vectors for cell transfection Bioconjug Chem 2012;23:993-1002
15. Probst G, Xu Y Small molecule BACE1 inhibitors: a patent literature review (2006-2011) Expert Opinion Ther Patents 2012;22:511-40
16. Citron M Alzheimer's disease: strategies for disease modification Nat Rev Drug Discov 2010;9:387-98
17. Astra Zeneca Pharmaceuticals LP Thiazol-guanidine derivatives useful as a (beta)-related pathologies US0298340; 2010
18. Gerritz SW, Zhai W, Shi S, et al Acyl guanidine inhibitors of beta-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid-and solution-phase library synthesis J Med Chem 2012;55:9208-23
19. Lopez LC, Dos-Reis S, Espargaro A, et al Discovery of novel inhibitors of amyloid beta-peptide 1-42 aggregation J Med Chem 2012;55:9521-30
20. Schmuck C, Frey P, Heil M Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors ChemBioChem 2005;6:628-31
21. Anzini M, Chelini A, Mancini A, et al Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino-(6-trifluomethoxy) benzothiazole as neuroprotective agents potentially useful in brain diseases J Med Chem 2010;53:734-44
22. Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies US0197670; 2010
23. Bioalvo-Servicos, Investigcao e Desenvolvimento em Biotechnologia S.A WO123486; 2009
24. Ribeiro MMB, Pinto ART, Domingues MM, et al Chemical conjugation of the neuropeptide kyotorphin and ibuprofen enhances brain targeting and analgesia Mol Pharm 2011;8:1929-40
25. University of South Florida N,N'-di-pbromophenyl guanidine treatment for stroke at delayed timepoints WO048164; 2010
26. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke NEJM 1995;333:1581-8
27. Katnik C, Guerrero WR, Pennypacker KR, et al Sigma-1 receptor activation prevents intracellular calciumdysregulation in cortical neurons during in vitro ischemia J Pharmacol Exp Ther 2006;319:1355-65
28. WaPharm AB Use of hydroxyguanidines US6599943; 2003
29. Shire LLC Prodrugs of guanfacine US0065796; 2011
30. Strange BC Once-daily treatment of ADHD with guanfacine: patient implications Neuropsychiatr Dis Treat 2008;4:499-506
31. The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea Guanidine based compounds WO080818; 2009
32. The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabe A2-Adrenoceptor ligands US0160332; 2010
33. Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Guanidine based compounds US0331384; 2010
34. Rodriguez F, Rozas I, Ortega JE, et al Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists 1: toward new antidepressants with heteroatomic linkers J Med Chem 2007;50:4516-27
35. Rodriguez F, Rozas I, Ortega JE, et al Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists 2: exploring alkyl linkers for new antidepressants J Med Chem 2008;51:3304-12
36. The McLean Hospital Corp., University of Utah Research Foundation Methods for treatment of psychiatric disorders WO143534; 2011
37. Abbot GmbH & Co KG Guanidinverbindungen Und Ihre Verwendung als Bindungspartner fuer 5-HT5-Rezeptoren EP2380885; 2011
38. Roche Palo Alto LLC Arylsulfonamidyl tetralin derivatives and uses thereof US7531577; 2009
39. Zajdel P, Subra G, Verdie P, et al Sulfonamides with N-alkyl-N'- dialkylguanidine moiety as 5-HT7 receptor ligands Bioorg Med Chem Lett 2009;19:4827-31
40. Neveu C, Lefranc B, Tasseau O, et al Rational design of low molecular weight, stable, potent, and long-lasting GPR103 Aza-beta3-pseudopeptide agonist J Med Chem 2012;55:7516-24
41. Ustav Organicke Chemie a Biochemie Akademie ved Ceske Republiky, V.V.I, Fyziologicky Ustav Akademie ved Ceske Republiky, V.V.I Pregnanolone derivatives substituted in 3alpha-position with the cationic group, method of their production, usage and pharmaceutical preparation involving them WO110010; 2012
42. Pryma D, Divgi C Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors Nucl Med Biol 2008;35:S1:3-8
43. Gourand F, Mercey G, Ibazizene M, et al Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system J Med Chem 2010;53:1281-7
44. Robins EG, Zhao Y, Khan I, et al Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: novel high-affinity NMDA receptor antagonists for imaging with PET Bioorg Med Chem Lett 2010;20:1749-51
45. Santangelo RM, Acker TM, Zimmerman SS, et al Novel NMDA receptor modulators: an update Expert Opinion Ther Patents 2012;22:1337-52
46. GE Healthcare Ltd Method of synthesis WO141568; 2011
47. Anderssohn M, Schwedhelm E, Luneburg N, et al Review article: asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus Diab Vasc Dis Res 2010;7:105-18
48. Marcovecchio ML, Dalton RN, Turner C, et al Symmetric dimethylarginine, an endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes Arch Dis Child 2010;95:119-24
49. Biocrates Life Sciences AG Method and use of metabolites for the diagnosis of inflammatory brain injury in preterm born infants EP2492690; 2011
50. Busso N, Karababa M, Nobile M, et al Pharmacological ed to NAD PLOS 2008;3:e2267; 1-10
51. Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety WO121055; 2011
52. Pishvaian MJ, Marshall JL, Hwang JJ, et al A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion J Clin Oncol 2009;27:15s
53. Olesen UH, Christensen MK, Bjorkling F, et al Anticancer agent CHS-828 inhibits cellular synthesis of NAD Biochem Biophys Res Commun 2008;367:799-804
54. Kato H, Ito E, Shi W, et al Efficiency of combining GMX1777 with radiation therapy for human head and neck carcinoma Clin Cancer Res 2010;16:898-911
55. Takeda Pharmaceutical Co Ltd N-substituted oxazinopteridines and oxazinopteridinones US0220575; 2012
56. Hirsch E, Ciraolo E, Ghigo A, Costa C Taming the PI3K team to hold inflammation and cancer at bay Pharm Ther 2008;118:192-205
57. Intellikine, Inc Heterocyclic compounds and uses thereof WO149937; 2011
58. Trustees of Dartmouth College Inhibitors of the trypsin-like site of the proteasome and methods of use thereof US0214732; 2012
59. Allergan, Inc Cyclosporin derivatives for treating inflammatory diseases and conditions WO138423; 2010
60. Allegro Pharmaceuticals, Inc Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites WO060104; 2011
61. Cytokine Pharmasciences, Inc Guanylhydrazones for treatment of postoperative intestinal inflammation WO039429; 2010
62. Oke SL, Tracey KJ From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex J Leukoc Biol 2008;83:512-17
63. Kalypsys, Inc Bicyclic heteroaryl inhibitors of PDE4 WO093924; 201164 Rhode Island Hospital Stromal derived factor inhibition and CXCR4 blockade WO112919; 2012
64. Liang X CXCR4, inhibitors and mechanisms of action Chem Biol Drug Des 2008;72:97-110
65. Zhan W, Liang Z, Zhu A, et al Discovery of small molecule CXCR4 antagonists J Med Chem 2007;50:5655-64
66. Lim HD, Adami M, Guaita E, et al Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430 Br J Pharmacol 2009;157:34-43
67. Anamar AB Compounds for treatment of inflammation WO012868; 2011
68. Lim HD, Smits RA, Bakker RA, et al Discovery of S-(2-Guanidylethyl)- isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist J Med Chem 2006;49:6650-1
69. Kiss R, Keseru GM Histamine H4 receptor ligands and their potential therapeutic applications: an update Expert Opinion Ther Patents 2012;22:205-21
70. Piramal Life Sciences Ltd Tricyclic guanidine derivatives as sodium-proton exchange inhibitors US0267690; 2010
71. Boehringer Ingelheim International GmbH Pyrrolidinyl and piperidinyl compounds useful as NHE-1 inhibitors WO005783; 2010
72. Katholieke Universiteit Leuven Synucleinopathies WO094090; 2010
73. Morshedi D, Aliakbari F The inhibitory effects of cuminaldehyde on amyloid fibrillation and cytotoxicity of alpha-synuclein Modares J Med Sci Pathobiol 2012;15:45-60
74. Mao D, Xu Y, Hu X, et al Synthesis and Na+/H+ exchanger-1 inhibitory activity of substituted (Quinolinecarbonyl)guanidine derivatives Chem Biodivers 2009;6:1727-36
75. Lee S, Yi KY, Youn SJ, et al (2-Aryl-5-methylimidazol-4-ylcarbonyl) guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl) guanidines as NHE-1 inhibitors Bioorg Med Chem Lett 2009;19:1329-31
76. Schwark JR, Jansen HW, Lang HJ, et al S3226, a novel inhibitor of Na+/H+ exchanger subtype 3 in various cell types Pflugers Arch 1998;436:797-800
77. Miyanga W, Shima Y, Noguchi K, et al Novel acylguanidine derivatives US008219; 2011
78. Rodgers HC, Knox AJ The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis Eur Respir J 1999;14:693-6
79. Parion Sciences, Inc Poly aromatic sodium channel blockers US0214444; 2009
80. Kainos Medicine, Inc Production method of phenyl guanidine salts and their intermediates WO156355; 2011
81. Gledhill JR, Montgomery MG, Leslie AGW, Walker JE Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols PNAS 2007;104:13632-7
82. Bristol-Myers Squibb Co (1-Phenyl-2-heteroaryl)ethylguanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase US6916813; 2005
83. The regents of the University of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods WO030891; 2010
84. Lycera Corp Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof WO078874; 2012
85. Lycera Corp Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof WO078869; 2012
86. Lycera Corp Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof WO078867; 2012
87. Kotthaus J, Schade D, Muschick N, et al Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase- 1: alkenyl-amidines as new leads Bioorg Med Chem 2008;16:10205-9
88. Wang Y, Monzingo AF, Hu S, et al Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide Biochemistry 2009;48:8624-35
89. UCL Biomedica PLC c/o Finance Division University College of London Guanidine derivatives as inhibitors of DDAH US0069331; 2009
90. Eldrug S.A Compounds WO016514; 2009
91. Tovbin, Dmitry Gennadievich Urethanes, ureas, amidines and related inhibitors of factor Xa WO108963; 2011
92. Nektar Therapeutics Al, Corp Oligomer-guanidine class conjugates WO089053; 2009
93. Stealth Peptides International, Inc Methods for performing a coronary artery bypass graft procedure WO082328; 2011
94. Gundewar S, Calvert JW, Iha S, et al Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival heart failure Circ Res 2009;104:403-11
95. Inserm, CHU Nantes, Universite de Nantes 5'-Adenosine monophosphate-activated protein kinase (MAPK) activators for treating pulmonary hypertension WO103040; 2010
96. Lantheus Medical Imaging, Inc Compositions, methods and systems for the synthesis and use of imaging agents WO143360; 2011
97. Indigene Pharmaceuticals, Inc Compositions and methods for treating diabetes WO056726; 2010
98. Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH Substituted 5-,6-and 7-membered heterocycles, medicaments containing such compounds, and their use WO159760; 2011
99. Satiogen Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of obesity and diabetes US0157399; 2012
100. Satiogen Pharmaceuticals, Inc Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions WO150286; 2011
101. Satiogen Pharmaceuticals, Inc Bile acid recycling inhibitors and for treatment of obesity and diabetes US0130472; 2010
102. Biospherics, Inc D-Tagatose and biguanide compositions and methods WO123236; 2011
103. University of Eastern Finland Novel prodrugs of metformin WO100337; 2010
104. Lynn Megeney, Carol Evans, Abdelmalik Slassi Treatment of muscle disease characterized by insulin resistance US0065176; 2012
105. Tassoni E, Giannessi F, Brunetti T, et al Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents J Med Chem 2008;51:3073-6
106. Coxon GD, Furman BL, Harvey AL, et al Benzylguanidines and other galegine analogues inducing weight loss in mice J Med Chem 2009;52:3457-63
107. Carafa V, Miceli M, Altucci L, Nebbioso A Histone deacetylase inhibitors: a patent review (2009-2011) Expert Opinion Ther Patents 2013;23:1-17
108. Rotili D, Mai A Targeting histone demethylases: a new avenue for the fight against cancer Genes Cancer 2011;2:663-79
109. Shi Y, Lan F, Matson C, et al Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 2004;119:941-53
110. Lizcano F, Garcia J Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets Pharmaceuticals 2012;5:963-90
111. Zhu Q, Huang Y, Marton LJ, et al Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells Amino Acids 2012;42:887-98
112. The Johns Hopkins University, Progen Pharmaceuticals Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (DFMO) WO113005; 2011
113. Deng J, Taheri L, Grande F, et al Discovery of novel anticancer compounds based on a quinoxalinehydrazine pharmacophore ChemMedChem 2008;3:1677-86
114. University of Southern California Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore US0160313; 2010
115. French KJ, Upson JJ, Keller SN, et al Antitumor activity of sphingosine kinase inhibitors JPET 2006;318:596-603
116. Nishiuma T, Nishimura Y, Okada T, et al Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model Am J Physiol Lung Cell Mol Physiol 2008;294:1085-93
117. French KJ, Schrecengost RS, Lee BD, et al Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Res 2003;63:5962-9
118. French KJ, Zhuang Y, Maines LW, et al Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2 JPET 2010;333:129-39
119. Musc Foundation for Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase WO078247; 2010
120. Stupp R, Ruegg C Integrin inhibitors reaching the clinic J Clin Oncol 2007;25:1637-8
121. Universita degli Studi di Firenze 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors WO098603; 2011
122. Zanardi F, Burreddu P, Rassu G, et al Discovery of subnanomolar arginineglycine-aspartate-based alphavbeta3/alphavbeta5 integrin binders embedding 4-aminoproline residues J Med Chem 2008;51:1771-82
123. Binderup E, Bjorkling F, Hjarnaa PV, et al EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828 Bioorg Med Chem Lett 2005;15:2491-4
124. Gilling A, Majjigapu SR, Sordat B, Vogel P Synthesis of a C-iminoribofuranoside analog of the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866 Helv Chim Acta 2012;95:34-42
125. Esposito E, Impellizzeri D, Mazzon E, et al The NAMPT inhibitor FK866 reverts the damage in spinal cord injury J Neuroinflammation 2012;9:66-76
126. Forma Therapeutics, Inc Guanidine compounds and compositions for the inhibition of NAMPT WO031199; 2012
127. Topotarget A/S Novel cyanoguanidines WO086835; 2009
128. Topotarget A/S Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase WO142735; 2010
129. Myrexis, Inc Compounds and therapeutic uses thereof WO109441; 2011
130. Dowling RJO, Goodwin PJ, Stambolic V Understanding the benefit of metformin use in cancer treatment BMC Med 2011;9:33-8
131. Merck Patent GmbH, Inserm (Institut National de la Sante et de la Recherche Medicale) Biguanide compounds and its use for treating cancer WO147528; 2011
132. Sahebjam S, Siu LL, Razak AA The utility of hedgehog signaling pathway inhibition for cancer Oncologist 2012;17:1090-9
133. Peukert S, Miller-Moslin K Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics ChemMedChem 2010;5:500-12
134. Hadden MK Hedgehog pathway inhibitors: a patent review (2009-present) Expert Opinion Ther Patents 2013;23:345-61
135. Universite de Strasbourg, Centre national de la recherche scientifique Acyl guanidine derivatives modulating the Hedgehog protein signaling pathway US0196865; 2012
136. Brozewicz K, S?awinski J 1-(2-Mercaptobenzenesulfonyl)-3- hydroxyguanidines-Novel potent antiproliferatives, synthesis and in vitro biological activity Eur J Med Chem 2012;55:384-94
137. Ueda S, Kato M, Inuki S, et al Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach Bioorg Med Chem Lett 2008;18:4124-9
138. Colombo E, Desilets A, Duchene D, et al Design and Synthesis of Potent, Selective Inhibitors of Matriptase ACS Med Chem Lett 2012;3:530-4
139. Basu A, Sinha BN, Saiko P, et al NHydroxy-N'-aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation Bioorg Med Chem Lett 2011;21:3324-8
140. Qian Y, Zhang H-J, Lv P-C, Zhu H-L Synthesis, molecular modeling and biological evaluation of guanidine derivatives as novel antitubulin agents Bioorg Med Chem 2010;18:8218-25
141. Zhang H-Z, Crogan-Grundy C, May C, et al Discovery and structure-activity relationship of (2-(arylothio)-benzylideneamino)guanidines as a novelseries of potent apoptosis inducers Bioorg Med Chem 2009;17:2852-8
142. Murtaza G, Rauf MK, Badshah A, et al Synthesis, structural characterization and in vitro biological screening of some homoleptic copper(II) complexes with substituted guanidines Eur J Med Chem 2012;48:26-35
143. Zhou H, Liu L, Huang J, et al Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction J Med Chem 2013;56:1113-23
144. Universitat Zurich Preparation and uses of guanidinium-modified porphyrins and phthalocyanines WO028780; 2010
145. Marina Biotech, Inc Nucleic acid compounds for inhibiting FGFR3 gene expression and uses thereof WO139842; 2011
146. Adami RC, Seth S, Harvie P, et al An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA Mol Ther 2011;19:1141-51
147. Biotrom Ltd Hepatitis C antiviral compositions and methods WO018609; 2009
148. Bristol-Myers Squibb Co Compounds for the treatment of hepatitis C WO139513; 2011
149. Lathrop & Gage LLP 4845 Pearl East Circle, Suite 201 Boulder, Co 80301 Small antiviral peptides against hepatitis C virus US0233868; 2009
150. Yissum Research Development Co of The Hebrew University of Jerusalem Ltd Macrocyclic compounds, compositions comprising them and methods for preventing or treating HIV infection WO024175; 2011
151. Trana Discovery, Inc Antiviral compounds and methods of the use thereof WO113060; 2011
152. TSRL, Inc Neuraminidase inhibitors WO123856; 2011
153. Fuzians Biomedicals, Inc., The UAB Research Foundation Compounds useful as antiviral agents, compositions, and methods of use WO160024; 2011
154. TSRL, Inc Prodrugs of neuraminidase inhibitors WO129305; 2009
155. Cadila Healthcare Ltd Process for the preparation of zanamivir WO114350; 2012
156. Cheng T-JR, Weinheimer S, Tarbet EB, et al Development of oseltamivir phosphonate congeners as anti-influenza agents J Med Chem 2012;55:8657-70
157. Liu K-C, Fang J-M, Jan J-T, et al Enhanced anti-influenza agents conjugated with anti-inflammatory activity J Med Chem 2012;55:8493-501
158. Manfredi Amedea Giuseppina, CISI S.C R.L Consorzio interdisciplinare di studi biomolecolari e applicazioni industriali Anti-viral agents and compositions thereof WO145056; 2011
159. Ferruti Paolo, Cavalli Roberto, Ranucci Elisabetta Non-viral nucleic acid molecules delivery systems EP2388016; 2011
160. Ferruti P, Franchini J, Bencini M, Ranucci E Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic, nonhemolytic and "stealthlike" DNA complexing agent and transfection promoter Biomacromolecules 2007;8:1498-504
161. Achaogen, Inc Antibacterial derivatives of tobramycin WO132760; 2010
162. Achaogen, Inc Treatment of urinary tract infections with antibacterial aminoglycoside compounds WO132777; 2010
163. Achaogen, Inc Antibacterial derivatives of sisomicin WO132768; 2010
164. Achaogen, Inc Antibacterial aminoglycoside analogs WO132765; 2010
165. Achaogen, Inc Antibacterial aminoglycoside analogs WO030704; 2010
166. Deakin University Dioxolane norbornane/norbornene compounds suitable as antimicrobial agents to treat bacterial infections WO099573; 2010
167. Knobbe Martens Olson & Bear LLP Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof US0152098; 2010
168. Polymedix, Inc Synthetic mimetics of host defense and uses thereof WO062573; 2010
169. Instytut Chemii Organicznej, Polska Akademia Nauk Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof WO033043; 2010
170. Allaccem, Inc Bridged polycyclic compound based compositions for topical and oral applications WO019611; 2010
171. Fob Synthesis Carbapenem antibacterials with Gram-negative activity WO160020; 2011
172. Rutgers, The State University of New Jersey, University of Medicine and Dentistry of New Jersey Antimicrobial agents WO163610; 2011
173. Rutgers, The State University of New Jersey, University of Medicine and Dentistry of New Jersey Antimicrobial agents WO156626; 2011
174. Lytix Biopharma AS Methods of peptide modification US0143384; 2011
175. Lytix Biopharma AS Methods of peptide modification WO081151; 2009
176. Lytix Biopharma AS Therapeutic peptides WO051692; 2011
177. Lytix Biopharma AS Antimicrobial compounds WO081152; 2009
178. Allergan, Inc Combinations of preservatives for ophthalmic compositions WO127151; 2011
179. Centre National de la Recherche Scientifique (C.N.R.S.) Novel antimicrobial compositions, use and preparation thereof EP2386589; 2011
180. Nosopharm, Institut National de la Recherche Agronomique Nemaucin, an antibiotic produced by entomopathogenic Xenorhabdus cabanillasii WO085177; 2012
181. Lytix Biopharma AS Bioactive alkaloids WO035305; 2012
182. Tadesse M, Strm MB, Svenson J, et al Synoxazolidinones A and B: novel bioactive alkaloids from the ascidian Synoicum pulmonaria Org Lett 2010;12:4752-5
183. Kline T, Felise HB, Barry KC, et al Substituted 2-imino-5- arylidenethiazolidin-4-one inhibitors of bacterial type III secretion J Med Chem 2008;51:7065-74
184. Kline T, Barry KC, Jackson SR, et al Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system Bioorg Med Chem Lett 2009;19:1340-3
185. Tsou LK, Dossa PD, Hang HC Small molecules aimed at type III secretionsystems to inhibit bacterial virulence Med Chem Comm 2013;4:68-79
186. Massachusetts Institute of Technology US0249051; 2010
187. Mo S, Krunic A, Pegan SD, et al An antimicrobial guanidine-bearing sesterterpene from the cultured Cyanobacterium Scytonema sp J Nat Prod 2009;72:2043-5
188. Rodriguez F, Rozas I, Kaiser M, et al New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity J Med Chem 2008;51:909-23
189. Arafa RK, Wenzler T, Brun R, et al Molecular modeling study and synthesis of novel dicationic flexible triaryl guanidines and imidamines as antiprotozoal agents Eur J Med Chem 2011;46:5852-60
190. McKeever C, Kaiser M, Rozas I Aminoalkyl derivatives of guanidine diaromatic minor groove binders with antiprotozoal activity J Med Chem 2013;56:700-11
191. Polymedix, Inc., The Trustees of The University of Pennsylvania Anti-malarial compounds WO014573; 2010
192. The United States of America, as represented by the secretary of the Army, on behalf of U.S Army Medical Research and Materiel Command New imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use WO051129; 2010
193. Rosenthal PJ Cysteine proteases of malaria parasites Int J Parasitol 2004;34:1489-99
194. Julius-Maximilians-Universitat Wurzburg, Technische Universitat Carolowilhelmina za Braunschweig N-protected guanidine-substituted furans, thiophenes, and pyrrols as cysteine protease inhibitors WO037536; 2010
195. University of Georgia Research Foundation, Inc Anti-trypanosomal peptides and uses thereof WO129267; 2010
196. Castagnolo D, Raffi F, Giorgi G, Botta M Macrocyclization of di-Bocguanidino-alkylamines related to guazatine components iscovery and synthesis of innovative macrocyclic amidinoureas Eur J Org Chem 2009;334-7
197. Manetti F, Castagnolo D, Raffi F, et al Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp and Aspergillus spp J Med Chem 2009;52:7376-9
198. Universita degli Studi di Siena Linear and cyclic guanidine derivatives, method of preparation and uses thereof WO113033; 2009
199. Straetmans high TAC GmbH Synergistische Kombination von einem oder mehreren Fungiziden mit Guanidiniumsalzen EP2196091; 2008
200. Nosopharm, Institut National de la Recherche Agronomique Cabanillasin, a new antifungal compound, produced by entomopathogenic xenorhabdus cabanillasii EP2468718; 2010
201. Sisay MT, Steinmetzer T, Stirnberg M, et al Identification of the First Low-Molecular-Weight Inhibitors of Matriptase-2 J Med Chem 2010;53:5523-35
202. Silvestri L, Pagani A, Noi A, et al The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin Cell Metab 2008;8:502-11
203. L'Oreal Amino acid derivatives; compositions containing them; use as agents for treating human perspiration WO157612; 2011
204. L'Oreal Use of novel amino acid derivatives as agents for treating human perspiration, and compositions containing them WO157610; 2011
205. Gencia Corp Mitochondrial compositions and uses thereof WO033130; 2009
206. Massachusetts Institute of Technology Dendrimer-based excipients for the attenuation of protein aggregation WO065082; 2012
207. Trout BL, Wang DIC, Baynes BM Solution additives for the attenuation of protein aggregation US0247991; 2008
208. UCL Business PLC Process for the preparation of guanidino substituted biand polyphenyls that are suitable as small molecule carriers WO027679; 2009
209. UCL Business PLC New compounds WO097604; 2010
210. Thermolife International, LLC Amino acid compositions US0313042; 2011
211. Hettiarachchy NS Bioactive pentapeptides from rice bran and use thereof US0152180; 2011
212. Flamel Technologies S.A., Monsanto Technology LLC N- phosphonomethylglycine guanidine derivative salts US0172220; 2012